Vascular endothelial growth factor and amyotrophic lateral sclerosis: The interplay with exercise and noninvasive ventilation

Muscle and Nerve

Volumn 49, Issue 4, 2014, Pages 545-550

  Carilho, Rita ^a   De Carvalho, Mamede ^b,c   Swash, Michael ^c,d   Pinto, Susana ^c   Pinto, Anabela ^b,c   Costa, Júlia ^a  

^a INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA   (Portugal)

^b HOSPITAL DE SANTA MARIA   (Portugal)

^c INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Amyotrophic lateral sclerosis; Biomarker; Exercise; Noninvasive ventilation; Plasma VEGF levels

Indexed keywords

VASCULOTROPIN;

ADULT; AEROBIC EXERCISE; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CARBON DIOXIDE TENSION; CONTROLLED STUDY; DISEASE DURATION; EXERCISE; FEMALE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONINVASIVE VENTILATION; OXYGEN CONSUMPTION; OXYGEN TENSION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION; VERY ELDERLY; YOUNG ADULT;

AMYOTROPHIC LATERAL SCLEROSIS; BIOMARKER; EXERCISE; NONINVASIVE VENTILATION; PLASMA VEGF LEVELS;

AGED; AGED, 80 AND OVER; AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL MARKERS; EXERCISE; EXERCISE TEST; FEMALE; HUMANS; MALE; MIDDLE AGED; NONINVASIVE VENTILATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84896141517     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23955     Document Type: Article

References (28)

1. Costa J, Gomes C, de Carvalho M. Diagnosis, pathogenesis and therapeutic targets in amyotrophic lateral sclerosis. CNS Neurol Disord Drug Targets 2010;9:764-778.
2. Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motor neurons against ischaemic death. Nat Genet 2003;34:383-394.
3. Van Vught PWJ, Sutedja NA, Veldink JH, Koeleman BPC, Groeneveld GJ, Wimemga C, et al. Lack of association between VEGF polymorpisms and ALS in a Dutch population. Neurology 2005;65:1643-1645.
4. Lambrechts D, Posen K, Fernandez-Santiago R, Al-Chalabi A, Del Bo R, Van Vught PW, et al. Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the -2578AA genotype. J Med Genet 2009;46:840-846.
5. Carmeliet P, Storkebaum E. Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders. Semin Cell Dev Biol 2002;13:39-53.
6. Storkebaum E, Lambrechts D, Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 2004;26:943-954.
7. Brooks BR, Miller RG, Swash M, Munsat TL, for the World Federation of Neurology Research Committee on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2000;1:293-300.
8. De Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, et al. Electrodiagnostic criteria for the diagnosis of ALS. Clin Neurophysiol 2008;119:497-503.
9. Cedarbaum JM, Stambler N. Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials. J Neurol Sci 1997;152(Suppl):S1-S9.
10. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999;169:13-21.
11. Pinto S, Swash M, de Carvalho M. Respiratory exercise in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2012;13:33-44.
12. De Carvalho M, Costa J, Pinto S, Pinto A. Percutaneous nocturnal oximetry in amyotrophic lateral sclerosis: periodic desaturation. Amyotroph Lateral Scler 2009;10:154-161.
13. American Thoracic Society/ American College of Chest Physicians. ATS/ACCP Statement on Cardiopulmonary Exercise Testing. Am J Respir Crit Care Med 2003;167:211-277.
14. Borg GA. Psychophysical basis of perceived exertion. Med Sci Sports Exerc 1982;14:377-381.
15. Samjak M, Bravver E, Bockenek WL, Norton J, Brooks BR. Supported treadmill ambulation for amyotrophic lateral sclerosis: a pilot study. Arch Phys Med Rehabil 2010;91:1920-1929.
16. Hormbrey E, Gillespie P, Turner K, Han C, Roberts A, McGrouther D, et al. A critical review of vascular endotelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful? Clin Exp Metastasis 2002;19:651-663.
17. Nobile-Orazio E, Terenghi F, Giannotta C, Gallia F, Nozza A. Serum VEGF levels in POEMS syndrome and in imune-meditated neuropathies. Neurology 2009;72:1024-1026.
18. Lee S-C, Lee K-Y, Kim Y-J, Kim SH, Koh S-H, Lee YJ. Serum VEGF levels in acute ischaemic strokes are correlated with long-term prognosis. Eur J Neurol 2010;17:45-51.
19. Storkebaum E, Lambrechts D, Dewerchin M, Moreno-Murciano MP, Appelmans S, Oh H, et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 2005;8:85-92.
20. Nygren I, Larsson A, Johansson A, Askmark H. VEGF is increased in serum but not in spinal cord from patients with amyotrophic lateral sclerosis. Neuroreport 2002;13:2199-2201.
21. Just N, Moreau C, Lassalle P, Gosset P, Perez T, Brunaud-Danel V, et al. High erythropoietin and low vascular endothelial growth factor levels in cerebrospinal fluid from hypoxemic ALS patients suggest an abnormal response to hypoxia. Neuromuscul Disord 2007;17:169-173.
22. Devos D, Moreau, C, Lassalle, Perez T, De Seze J, Brunaud-Danel V, et al. Low levels of the vascular endothelial growth factor in CSF from early ALS patients. Neurology 2004;62:2127-2129.
23. Moreau C, Devos D, Brunaud-Danel V, Defebvre L, Perez T, Destée A, et al. Paradoxical response of VEGF expression to hypoxia in CSF of patients with ALS. J Neurol Neurosurg Psychiatry 2006;77:255-257.
24. Gupta PK, Prabhakar S, Sharma S, Anand A. Vascular enothelial growth factor-A (VEGF-A) and chemokine ligand-2 (CCL2) in amyotrophic lateral sclerosis (ALS) patients. J Neuroinflammation 2011;8:47.
25. Ilzecka J. Cerebrospinal fluid vascular endotelial growth factor in patients with amyotrophic lateral sclerosis. Clin Neurol Neurosurg 2004;106:289-293
26. Moreau C, Gosset P, Brunaud-Danel V, Lassalle P, Degone B, Destee A, et al. CSF profiles of angiogenic and inflammatory factors depend on the respiratory status of ALS patients. Amyotroph Lateral Scler 2009;10:175-181.
27. Moreau C, Gosset P, Kluza J, Brunaud-Danel V, Lassalle P, Marchetti P, et al. Deregulation of the hypoxia inducible factor-1α pathway in monocytes from sporadic amyotrophic lateral sclerosis patients. Neuroscience 2011;172:110-117.
28. Breen EC, Johnson EC, Wagner H, Tseng HM, Sung LA, Wagner PD. Angiogenic growth factor mRNA responses in muscle to a single bout of exercise. J Appl Physiol 1996;81:355-361.